- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02442531
A Study of CriPec® Docetaxel Given to Patients With Solid Tumours (NAPOLY)
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Leuven, Bélgica
- University Hospital Leuven
-
-
-
-
-
Amsterdam, Países Bajos
- VUMC Amsterdam
-
Groningen, Países Bajos
- UMC Groningen
-
Rotterdam, Países Bajos
- Erasmus Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- At least 18 years old
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Estimated life expectancy of at least 12 weeks
Ability and willingness to give written informed consent and to comply with the requirements of the study
For Part 1:
Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive solid tumours that are refractory to standard therapy or for whom no standard therapy exists and with measurable or evaluable disease according to RECIST 1.1.
For Part 2:
- Patients with pathologically confirmed diagnosis of advanced, recurrent and progressive cancer with measurable disease according to RECIST 1.1 of a histological type that are refractory to standard therapy or for whom no standard therapy exists and where treatment with a taxane is an appropriate treatment option.
Exclusion Criteria:
- Less than 4 weeks since the last treatment of chemotherapy, biological therapy, immunotherapy or systemic radiotherapy (except palliative radiation delivered to <20% of bone marrow), and less than 6 weeks for nitrosoureas and mitomycin C prior to Cycle 1 Day 1.
- Current or recent (within 4 weeks prior to Cycle 1 Day 1) treatment with another Investigational Product or participation in another investigational interventional study.
- Symptomatic brain metastases.
- Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) that have not resolved to ≤ grade 2 (as defined by CTCAE version 4.03).
Inadequate bone marrow function at screening as evidenced by any of the following:
- Absolute Neutrophil Count (ANC) < 1.5 x 109/L.
- Platelet count < 100 x 109/L.
- Haemoglobin < 6.0 mmol/L (< 9.6 g/dL). The patient should not have received a transfusion or growth factors for these abnormalities in the 7 days prior to Cycle 1 Day 1.
- Serum (total) bilirubin > 1.5 x the Upper Limit of Normal (ULN) for the institution if no liver metastases (> 2 x ULN in patients with liver metastases).
- AST or ALT > 2.5 x ULN if no liver metastases (> 5x ULN in patients with liver metastases).
- Alkaline phosphatase levels > 2.5 x ULN if no liver metastases (> 5 x ULN in patients with liver metastases, or > 10 x ULN in patients with bone metastases).
- Increased plasma prothrombin time or International Normalized Ratio (INR), consequence of reduced hepatic production of Vitamin K.
- Hepatitis B surface antigen or hepatitis C positivity with abnormal liver function tests.
Medical history of:
- Nonalcoholic steatohepatitis (NASH).
- History of human immunodeficiency virus (HIV) antibody positive or use of antiretroviral therapy.
- Alcoholic and autoimmune hepatitis.
- Ischemic hepatitis, Cardiovascular dysfunction or impaired liver oxygenation, including hypotension or right heart failure.
- Serum creatinine > 1.5 x ULN.
- Estimated Glomerular Filtration Rate of < 50 mL/min/1.73m2 calculated by Modification of Diet in Renal Disease (MDRD) formula or creatinine clearance of < 50 mL/min calculated by Cockcroft-Gault.
- Stroke within 6 months prior to Cycle 1 Day 1.
- Transient Ischemic Attack (TIA) within 6 months prior to Cycle 1 Day 1.
- Myocardial infarction within 6 months prior to Cycle 1 Day 1.
- Unstable angina.
- New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure at screening.
- Serious cardiac arrhythmia requiring medication.
- Patients who are pregnant or breastfeeding.
- Absence of effective means of contraception in female patients of childbearing potential (defined as <2 years after last menstruation and not surgically sterile) or in male patients who are not surgically sterile and who have female partners of childbearing potential.
- Major surgical procedure (including open biopsy and excluding central line intravenous catheter) within 28 days prior to the first study treatment, or anticipation of the need for major surgery during the course of the study treatment.
- Grade ≥2 motor or sensory neuropathy symptoms (as defined by CTCAE version 4.03).
- Known hypersensitivity to any of the Investigational Product's excipients or taxanes.
- History of drug or alcohol abuse in the opinion of the investigator within 3 years before screening.
- Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk for treatment-related complications.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: CriPec® docetaxel
Docetaxel containing nanoparticle
|
-3 weekly IV dose.
Dose escalation; start dose 15 mg/m2.
Number of cycles: 6 or until progression or unacceptable toxicity develops
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) as a measure of safety and tolerability.
Periodo de tiempo: 9 months
|
Part 1: Incidence of grade 3 or 4 adverse events (AEs) will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of clinical laboratory abnormalities as a measure of safety and tolerability.
Periodo de tiempo: 9 months
|
Part 1: Incidence of laboratory abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities as a measure of safety and tolerability.
Periodo de tiempo: 9 months
|
Part 1: Incidence of electrocardiogram (ECG) abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.
|
9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1.
Periodo de tiempo: 9 months
|
Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Periodo de tiempo: 9 months
|
Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1
Periodo de tiempo: 9 months
|
Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.
|
9 months
|
Part 1 and 2: Pharmacokinetic profile of CriPec® docetaxel following IV infusion
Periodo de tiempo: First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Pharmacokinetic parameters such as time to peak concentration (Tmax), peak concentration (Cmax), volume of distribution (Vd), half life (t1/2), total body clearance (CL) and area under the concentration-time curve (AUC) will be determined using plasma concentration data.
|
First two cycles of CriPec® docetaxel (each cycle is 3 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Early signs of anti-tumor efficacy (overall response rate [ORR]) of CriPec® docetaxel
Periodo de tiempo: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Early signs of anti-tumor efficacy (duration of response) of CriPec® docetaxel
Periodo de tiempo: 18 months in total for part 1 and 2
|
18 months in total for part 1 and 2
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CT-CL01
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Xinhua Hospital, Shanghai Jiao Tong University...Aún no reclutandoCANCER DE PROSTATA | Biopsia de próstataPorcelana
Ensayos clínicos sobre CriPec® docetaxel
-
Amsterdam UMC, location VUmcCristal TherapeuticsTerminado
-
Cristal TherapeuticsTerminadoEstudio de eficacia de CPC634 (CriPec® Docetaxel) en cáncer de ovario resistente al platino (CINOVA)Cáncer | Cáncer de ovariosPaíses Bajos, Bélgica, Reino Unido
-
Hoffmann-La RocheTerminadoCáncer de mamaPorcelana, Estados Unidos, Sudáfrica, Federación Rusa, Tailandia, Bosnia y Herzegovina, República Checa, India, Polonia
-
Korean Breast Cancer Study GroupDesconocidoCáncer de mama metastásico | Cáncer de mama recurrenteCorea, república de
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZenecaTerminadoCáncer de pulmón de células no pequeñasEstados Unidos
-
Hospira, now a wholly owned subsidiary of PfizerTerminadoCáncerReino Unido, Federación Rusa
-
Merck Sharp & Dohme LLCGOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)Activo, no reclutandoNeoplasias EndometrialesAustralia, Estados Unidos, Alemania, Israel, Corea, república de, Polonia, Pavo, Bélgica, Brasil, Canadá, Chile, Porcelana, Chequia, Dinamarca, Finlandia, Hungría, Irlanda, Italia, Japón, Países Bajos, Nueva Zelanda, Noruega, Federación... y más
-
Merck Sharp & Dohme LLCTerminadoTumores sólidos metastásicos localmente avanzados
-
Institut de Recherches Internationales ServierTerminadoLinfoma | Tumores sólidos avanzadosEstados Unidos, España, Francia
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ReclutamientoCáncer de mama HER2 positivoPorcelana